Empowering Lung Recovery with Doug Evans of Lungpacer
Med Tech Innovation Podcast hosts Kyle Kruse and Richard Meiklejohn interview Lungpacer CEO Doug Evans about the necessary but harmful impacts of mechanical ventilation, and how Lungpacer’s neurostimulation technology is designed to improve patient outcomes by rebuilding and maintaining diaphragm muscle function.
After Tragedy, an Entrepreneur’s Triumph
Brian Gormley of the Wall Street Journal publishes article on Lungpacer’s 15-year journey from a deeply personal mission sparked by a family tragedy to groundbreaking medical innovation. Nearly 2.5 million patients in the U.S. require mechanical ventilation each year, and for many, weaning off ventilation can be a struggle. Sadly, some never do. Research shows […]
Lungpacer announces 150th global patent for interventional neurostimulation technology portfolio
This 150th patent is a testament to our team’s ingenuity and dedication to serving the approximately 2.5 million US patients who require mechanical ventilation every year and our commitment to revolutionizing mechanical ventilation, creating a future where every patient can breathe easier and recover faster. With thanks to Viral Thakkar Kaitlin Taylor Matt Gani Gautam […]
Lungpacer Medical to Present Innovative Research at ATS 2025
Timothy Alexander of MyChesCo publishes article about Lungpacer’s upcoming research presentations at the American Thoracic Society (ATS) 2025 conference in San Francisco, California.
Philly weekly roundup: Commerce director steps down; Net neutrality in PA; Lungpacer Medical doubles workforce
Sarah Huffman of Technical.ly publishes article about Lungpacer Medical’s rapid growth to support sales of its FDA-approved AeroPace® System, and clinical study of its investigational AeroNova® System.
Harmony, Lungpacer, Verrica and Arbutus make C-suite hires
John George of the Philadelphia Business Journal publishes article about Lungpacer Medical’s recent hiring of a Chief Commercial Officer, Kevin Kearney, and plans for growth throughout the company.
Lungpacer Medical Names Kevin Kearney as Chief Commercial Officer
Timothy Alexander of MyChesCo publishes article about Lungpacer Medical hiring Kevin Kearney as CCO, to lead the commercialization effort of its FDA-approved AeroPace® System.
To Prep for First Product Launch, Exton’s Lungpacer Medical Doubles Workforce
Leah Mikulich at DELCO.TODAY publishes article about Lungpacer Medical’s anticipated growth for the commercial launch of its AeroPace® System after receiving FDA approval earlier this year.
Lungpacer Medical names Kevin Kearney as CCO
Medical Buyer publishes article about Kevin Kearney joining Lungpacer Medical as CCO as the company moves to commercialize its first FDA-approved product, the AeroPace® System.
Lungpacer Medical will nearly double workforce to support first product launch
John George of the Philadelphia Business Journal publishes article about Lungpacer Medical’s recent hiring, with plans to double its workforce and raise investment capital to commercialize its FDA-approved AeroPace® System, and conduct clinical trials for its investigational AeroNova® System.